Search results for "proportion"

showing 10 items of 877 documents

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab

2020

Abstract Background & Aims Radiological progression patterns to first‐line sorafenib have been associated with post‐progression and overall survival in advanced hepatocellular carcinoma, but these associations remain unknown for therapies in second‐ and later‐line settings. This post hoc analysis of REACH and REACH‐2 examined outcomes by radiological progression patterns in the second‐line setting of patients with advanced hepatocellular carcinoma treated with ramucirumab or placebo. Methods Patients with advanced hepatocellular carcinoma, Child‐Pugh A and Eastern Cooperative Oncology Group Performance Status 0 or 1 with prior sorafenib were randomized to receive ramucirumab 8mg/kg or place…

OncologySorafenibLiver CancerMalemedicine.medical_specialtyCarcinoma HepatocellularramucirumabPopulationRadioteràpiaAntineoplastic AgentsPlaceboAntibodies Monoclonal HumanizedRamucirumabLesionCàncer de fetge03 medical and health sciencesbest supportive care0302 clinical medicineInternal medicinePost-hoc analysisMedicineHumanseducationdisease progression patternseducation.field_of_studyHepatologyRadiotherapybusiness.industryProportional hazards modelLiver NeoplasmsMiddle AgedSorafenibmedicine.diseaseTreatment Outcome030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyOriginal Articlemedicine.symptombusinesspost‐progression survivalnew extrahepatic lesionLiver cancermedicine.drug
researchProduct

Association Between Tumor Egfr and Kras Mutation Status and Clinical Outcomes in Nsclc Patients Randomized to Sorafenib Plus Best Supportive Care (BS…

2012

ABSTRACT Background Tumor EGFR and KRas mutations are both predictive and prognostic biomarkers in patients with advanced NSCLC. We analyzed the correlation between these biomarkers and treatment outcomes in a phase III trial of 3rd/4th line sorafenib in patients with NSCLC. Methods The global, randomized, placebo-controlled MISSION trial enrolled 703 patients with advanced relapsed/refractory NSCLC of predominantly non-squamous histology. The primary study endpoint was overall survival (OS). EGFR and KRas mutations were analyzed in archival tumor samples and in circulating tumor DNA isolated from plasma. Results Tumor and/or plasma mutation data were available from 347 patients (49%). EGFR…

OncologySorafenibmedicine.medical_specialtyProportional hazards modelbusiness.industryHematologymedicine.disease_causePlacebomedicine.diseaseBreast cancerOncologyEgfr mutationInternal medicineMedicineBiomarker (medicine)KRASStage (cooking)businessmedicine.drugAnnals of Oncology
researchProduct

Dose-response relationship in the context of a maintenance randomized control trial: reanalysis of the PRODIGE 9 trial

2019

Introduction The dose-response relationship is considered as one of the major criteria when the causality of a relationship between an exposure and an outcome is discussed. This criterion is mainly studied in observational studies but may be also of interest in Randomized Controlled Trial (RCT), particularly if the administered dose of treatment varies over time and between patients. Maintenance trials with a long follow-up meet these characteristics. We reanalyzed a maintenance trial in digestive oncology (PRODIGE 9 trial) in order to explore the dose-response relationship between the maintenance treatment and overall survival (OS). Methods The PRODIGE 9 study was a maintenance trial asses…

Oncologyeducation.field_of_studymedicine.medical_specialtyRandomizationEpidemiologybusiness.industryProportional hazards modelPopulationPublic Health Environmental and Occupational HealthCumulative ExposureContext (language use)Lower risklaw.inventionRandomized controlled triallawInternal medicineMedicineObservational studybusinesseducationRevue d'Épidémiologie et de Santé Publique
researchProduct

Extranodal Extension of Nodal Metastases Is a Poor Prognostic Indicator in Gastric Cancer: a Systematic Review and Meta-analysis.

2016

Introduction: The extranodal extension (ENE) of nodal metastases (the extension of neoplastic cells through the nodal capsule into the perinodal soft tissue) is a histological feature that has been considered a prognostic factor in several cancers, but the role in gastric cancer was not yet investigated. We aimed to investigate the prognostic role of ENE in patients affected by gastric cancer through a systematic review and meta-analysis. Material and Methods: Two independent authors searched major databases until 09/30/2015 to identify studies providing data on gastric cancer patients’ prognostic parameters and comparing patients with ENE (ENE+) vs intra-nodal extension (ENE−). The data we…

Oncologymedicine.medical_specialty03 medical and health sciencesNodal Metastases Extranodal Extension Gastric Cancer0302 clinical medicineextranodal extension nodal metastases gastric cancerRecurrenceStomach NeoplasmsInternal medicineExtranodal extensionmedicineOdds RatioHumansGastric cancer . ENE . Extranodal extensionENE; Extranodal extension; Gastric cancer; Lymph node metastasis; Surgery; GastroenterologyProportional Hazards ModelsLymph node metastasisbusiness.industryProportional hazards modelNodal MetastasesHazard ratioConfoundingGastroenterologyCancerOdds ratiomedicine.diseasePrognosisConfidence interval030220 oncology & carcinogenesisMeta-analysisRelative riskLymphatic MetastasisENE030211 gastroenterology & hepatologySurgeryLymph NodesNeoplasm Recurrence LocalbusinessGastric cancerJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
researchProduct

Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

2009

Context The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor–positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen. The formation of active metabolites is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme. Objective To determine whether CYP2D6 variation is associated with clinical outcomes in women receiving adjuvant tamoxifen. Design, Setting, and Patients Retrospective analysis of German and US cohorts of patients treated with adjuvant tamoxifen for early stage breast cancer. The 1325 patients had diagnoses between 1986 and 2005 of stage I through III breast cancer and were mainly postmenopausal (9…

Oncologymedicine.medical_specialtyAntineoplastic Agents HormonalGenotypeBreast NeoplasmsArticleBreast cancerInternal medicinemedicineHumansskin and connective tissue diseasesSurvival analysisProportional Hazards ModelsPolymorphism GeneticProportional hazards modelbusiness.industryHazard ratioCancerGeneral Medicinemedicine.diseaseAntiestrogenSurvival AnalysisTamoxifenPhenotypeTreatment OutcomeEndocrinologyCytochrome P-450 CYP2D6PharmacogeneticsFemaleBreast diseasebusinessTamoxifenmedicine.drug
researchProduct

Detection methods predict differences in biology and survival in breast cancer patients

2012

Abstract Background The aim of this study was to measure the biological characteristics involved in tumorigenesis and the progression of breast cancer in symptomatic and screen-detected carcinomas to identify possible differences. Methods For this purpose, we evaluated clinical-pathological parameters and proliferative and apoptotic activities in a series of 130 symptomatic and 161 screen-detected tumors. Results After adjustment for the smaller size of the screen-detected carcinomas compared with symptomatic cancers, those detected in the screening program presented longer disease-free survival (RR = 0.43, CI = 0.19-0.96) and had high estrogen and progesterone receptor concentrations more …

Oncologymedicine.medical_specialtyCancer ResearchSurvivalProliferationBreast NeoplasmsApoptosisKaplan-Meier Estimatemedicine.disease_causelcsh:RC254-282Breast cancerBreast cancerSurgical oncologyInternal medicineDetection methodsmedicineGeneticsHumansMammographyEarly Detection of CancerProportional Hazards Modelsmedicine.diagnostic_testbusiness.industryProportional hazards modelDisease progressionCase-control studyMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosismedicine.diseaseImmunohistochemistryOncologyCase-Control StudiesDisease ProgressionImmunohistochemistryFemalebusinessCarcinogenesisMammographyResearch Article
researchProduct

Prognostic Impact of Immunoglobulin Kappa C in Breast Cancer Patients Treated with Adjuvant Chemotherapy.

2020

<b><i>Introduction:</i></b> Immunoglobulin κC (IGKC)-positive tumor-infiltrating plasma cells are associated with better prognosis in node-negative breast cancer patients without adjuvant systemic therapy. In the present study we evaluated the prognostic significance of IGKC in breast cancer patients treated with adjuvant chemotherapy ± tamoxifen. <b><i>Methods:</i></b> IGKC expression was immunohistochemically analyzed in 193 breast cancer patients who were treated with adjuvant chemotherapy, either with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) or 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) between 1993 and 2001 wit…

Oncologymedicine.medical_specialtyChemotherapyCyclophosphamideProportional hazards modelbusiness.industrymedicine.medical_treatmentHazard ratiomedicine.diseaseLog-rank testBreast cancerOncologyInternal medicinemedicineSurgerybusinessTamoxifenEpirubicinmedicine.drugResearch ArticleBreast care (Basel, Switzerland)
researchProduct

Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cel…

2011

Abstract Abstract 3089 Introduction: High-dose chemotherapy (HDT) and autologous stem-cell transplantation (ASCT) demonstrated high efficacy in the treatment of newly-diagnosed primary CNS lymphoma (PCNSL) in eligible patients (pts). Prognosis of PCNSL is associated with several clinical and histopathological risk factors (RF). Early complete response (CR) during chemotherapy (CHT) was recently reported to be an additional independent prognostic factor in pts undergoing polychemotherapy without HDT+ASCT. In this analysis, we examined the extent to which known RF determined survival in pts who were treated with HDT-ASCT. We additionally investigated the impact of HDT-ASCT specific factors (e…

Oncologymedicine.medical_specialtyChemotherapyPerformance statusbusiness.industryProportional hazards modelmedicine.medical_treatmentImmunologyPrimary central nervous system lymphomaCell BiologyHematologyThioTEPAmedicine.diseaseBiochemistryChemotherapy regimenSurgeryTransplantationInternal medicineMedicineStem cellbusinessmedicine.drugBlood
researchProduct

Prognostic factors for progression-free and overall survival in advanced biliary tract cancer

2015

BACKGROUND: Biliary tract cancer is an uncommon cancer with a poor outcome. We assembled data from the National Cancer Research Institute (UK) ABC-02 study and 10 international studies to determine prognostic outcome characteristics for patients with advanced disease.METHODS: Multivariable analyses of the final dataset from the ABC-02 study were carried out. All variables were simultaneously included in a Cox proportional hazards model, and backward elimination was used to produce the final model (using a significance level of 10%), in which the selected variables were associated independently with outcome. This score was validated externally by receiver operating curve (ROC) analysis using…

Oncologymedicine.medical_specialtyDisease-Free SurvivalCholangiocarcinoma03 medical and health sciencesAdvanced diseaseCisplatin and gemcitabine0302 clinical medicineInternal medicinemedicineJournal ArticleHumansProgression-free survivalProportional Hazards ModelsPerformance statusReceiver operating characteristicManchester Cancer Research Centrebusiness.industryProportional hazards modelResearch Support Non-U.S. Gov'tResearchInstitutes_Networks_Beacons/mcrcHazard ratioArea under the curveCancerHematologymedicine.diseasePrognosisConfidence intervalSurgeryTreatment OutcomeOncologyBile Duct NeoplasmsROC Curve030220 oncology & carcinogenesisABC-02Multivariate AnalysisBiliary tract cancer030211 gastroenterology & hepatologybusinessPerformance statusPrognostic modelMeta-Analysis
researchProduct

Comparison of genetic risk prediction models to improve prediction of coronary heart disease in two large cohorts of the MONICA/KORA study

2021

Abstract It is still unclear how genetic information, provided as single‐nucleotide polymorphisms (SNPs), can be most effectively integrated into risk prediction models for coronary heart disease (CHD) to add significant predictive value beyond clinical risk models. For the present study, a population‐based case‐cohort was used as a trainingset (451 incident cases, 1488 noncases) and an independent cohort as testset (160 incident cases, 2749 noncases). The following strategies to quantify genetic information were compared: A weighted genetic risk score including Metabochip SNPs associated with CHD in the literature (GRSMetabo); selection of the most predictive SNPs among these literature‐co…

Oncologymedicine.medical_specialtyEpidemiologyFramingham Risk Score ; Metabochip ; Coronary Heart Disease ; Genomic Risk Prediction ; Priority-lassoPopulationCoronary DiseaseSingle-nucleotide polymorphismKoronare HerzkrankheitPolymorphism Single NucleotideRisk AssessmentCohort Studies03 medical and health sciencesRisk FactorsInternal medicinemedicineHumansgenomic risk predictionddc:610coronary heart diseaseMetabochipGenetikeducationGenotypingGenetics (clinical)030304 developmental biologypriority‐Lasso0303 health scienceseducation.field_of_studyFramingham Risk ScoreModels GeneticProportional hazards modelbusiness.industry030305 genetics & heredityGenomicsConfidence intervalddc:Coronary disease; GeneticsRisk factorsCohortFramingham risk scorebusinessDDC 610 / Medicine & healthPredictive modelling
researchProduct